Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)

Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial

CBC Group acquires UCB's mature neurology and allergy business in China

Allergy Therapeutics begins Phase III trial for grass allergy treatment in children

Allergy Therapeutics announces Marketing Authorisation Application submission for Grass MATA MPL in Germany

Biopharmaceutical company BioVaxys partner SpayVac for Wildlife scales up vaccine production in Madison facility

IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial

ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices

IgGenix presents IGNX001 data at 2024 ASCIA

EURneffy approved in EU for needle-free anaphylaxis treatment

Anivive Lifesciences receives new contract from National Institute of Allergy and Infectious Diseases

The National Institute of Allergy and Infectious Diseases provides up to USD3m malaria vaccine development grant to Versatope Therapeutics

Crossject secures EUR6.9m French government grant to advance ZENEO Epinephrine

Allergy Therapeutics initiates subcutaneous dosing in peanut allergic patients for VLP Peanut PROTECT trial

Celltrion USA submits CT-P39 Biologics License Application to FDA